One of the Democrat talking points about ‘The Big Beautiful Bill’ is that the changes in healthcare policies present a threat to rural hospitals. The changes in the bill are actually not the problem, but there is something that does need to be fixed in order for rural hospitals to survive.
On Wednesday, Red State reported:
The Democrats have decided that they want to make the One Big Beautiful Bill their primary campaign talking point in 2026. They think that by focusing on Medicaid cuts, they can scare voters away from the Republican Party and back toward them for the midterms.
One of their focus points is how Medicaid cuts might impact rural hospitals. But the Democrats are also big proponents of doing away with the 340B drug program that those same hospitals rely on, and they aren’t lifting a finger to stop big pharmaceutical companies from trying to gut it however they can.
What’s Really Happening
Five major pharmaceutical companies—Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, and Sanofi—are pushing to fundamentally change how rural hospitals get discounted drugs. Instead of getting upfront discounts through the federal 340B program, these companies want to switch to a “rebate model” where hospitals pay full price first, then wait for pharmaceutical companies to maybe pay them back later.
Sound like a scam? That’s because it is.
The Numbers Don’t Lie
A new national survey by 340B Health shows just how devastating this change would be. The average critical access hospital—these are the small rural hospitals with 25 beds or fewer that serve communities across Louisiana and the rest of rural America—would have to float an extra $1.7 million per year to pharmaceutical companies.
Think about that for a minute. Rural hospitals that are already operating on razor-thin margins would suddenly have to come up with nearly $2 million in upfront cash, then wait for drug companies to process their rebate requests “using their own criteria and timelines.”
The article concludes:
But while Washington argues about Medicaid work requirements that might affect rural hospitals down the road, Big Pharma is actively working to destroy rural healthcare right now. And they’re counting on nobody paying attention.
The 340B program isn’t perfect—no federal program is. But it’s a lifeline for rural hospitals that serve the patients nobody else wants to treat. If we let pharmaceutical companies turn it into just another profit center, we’ll lose more than hospitals. We’ll lose entire communities.
It’s time to call this what it is: corporate greed masquerading as healthcare reform. And it’s time to stop it before it’s too late.
Please follow the link to read the entire article. This might be a really good time to examine the campaign contributions from pharmaceutical companies given to the Congressmen pushing this idea.